Safety Evaluation of LSCD101 Transplantation for Limbal Stem Cell Deficiency

Limbus Corneae Clinical Trial

Official title:
Phase I Study to Evaluate Safety of LSCD101(Cultured Autologous Limbal Epithelial Cell Sheet) Transplantation for Limbal Stem Cell Deficiency

Status Completed

Clinical Trial Summary

Clinical Study Objective: To evaluate the tolerability and safety after transplantation of LSCD101 in patients with intractable limbal stem cell deficiency Study Method: Subjects who finally meet the inclusion/exclusion criteria results of the subject eligibility evaluation will receive transplantation of the investigational product. Adverse drug reaction will be confirmed during 24 weeks after transplantation.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Corneal Diseases
Limbus Corneae
Limbus Corneae Insufficiency Syndrome

Clinical Trial Details

NCT number	NCT04773431
Study type	Interventional
Source	CliPS Co., Ltd
Contact
Status	Completed
Phase	Phase 1
Start date	January 31, 2020
Completion date	January 14, 2021

View Details

See also
	Status	Clinical Trial	Phase
	Active, not recruiting	`NCT02500134` - Using AS-OCT to Assess the Role of Age and Region in the Morphology and Epithelial Thickness of Limbus	N/A
	Recruiting	`NCT02886611` - Limbal Stem Cell Deficiency of Genetic Origin: Genotype-phenotype Correlation